Last reviewed · How we verify
Intravenous tirofiban combination therapy
Intravenous tirofiban combination therapy is a Small molecule drug developed by Shanghai East Hospital. It is currently in Phase 2 development. Also known as: Tirofiban.
At a glance
| Generic name | Intravenous tirofiban combination therapy |
|---|---|
| Also known as | Tirofiban |
| Sponsor | Shanghai East Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke (PHASE4)
- Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracranial Aneurysms (NA)
- Patient Selection Using MR With Non-Perfusion Imaging for Endovascular Treatment Within 6 to 24 Hours (NA)
- One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China (PHASE2)
- Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion (NA)
- A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke (PHASE2)
- Shanghai Registry of Acute Coronary Events
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous tirofiban combination therapy CI brief — competitive landscape report
- Intravenous tirofiban combination therapy updates RSS · CI watch RSS
- Shanghai East Hospital portfolio CI
Frequently asked questions about Intravenous tirofiban combination therapy
What is Intravenous tirofiban combination therapy?
Intravenous tirofiban combination therapy is a Small molecule drug developed by Shanghai East Hospital.
Who makes Intravenous tirofiban combination therapy?
Intravenous tirofiban combination therapy is developed by Shanghai East Hospital (see full Shanghai East Hospital pipeline at /company/shanghai-east-hospital).
Is Intravenous tirofiban combination therapy also known as anything else?
Intravenous tirofiban combination therapy is also known as Tirofiban.
What development phase is Intravenous tirofiban combination therapy in?
Intravenous tirofiban combination therapy is in Phase 2.
Related
- Manufacturer: Shanghai East Hospital — full pipeline
- Also known as: Tirofiban
- Compare: Intravenous tirofiban combination therapy vs similar drugs
- Pricing: Intravenous tirofiban combination therapy cost, discount & access